<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prognostic role of the glucometabolic status assessed in a metabolically stable phase after a first acute myocardial infarction: the SHEEP study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">I</forename><surname>Janszky</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Public Health Sciences</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Behavioural Sciences</orgName>
								<orgName type="institution">Semmelweis University</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Hallqvist</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Public Health Sciences</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Stockholm Centre for Public Health</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Ljung</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Public Health Sciences</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Centre for Epidemiology</orgName>
								<orgName type="institution">The National Board of Health and Welfare</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Ahlbom</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Stockholm Centre for Public Health</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Epidemiology</orgName>
								<orgName type="department" key="dep2">Institute of Environmental Medicine</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">N</forename><surname>Hammar</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Epidemiology</orgName>
								<orgName type="department" key="dep2">Institute of Environmental Medicine</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">AstraZeneca R&amp;D</orgName>
								<address>
									<addrLine>Mo ¨lndal</addrLine>
									<settlement>Epidemiology</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">Janszky I, Hallqvist J, Ljung R, Ahlbom A, Hammar N (Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Institute of Behavioural Sciences</orgName>
								<orgName type="institution">Semmelweis University</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">Stockholm Centre for Public Health</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Prognostic role of the glucometabolic status assessed in a metabolically stable phase after a first acute myocardial infarction: the SHEEP study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">CEFE077961DE456A7029BD7068DC9A62</idno>
					<idno type="DOI">10.1111/j.1365-2796.2008.02036.x</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.1" ident="GROBID" when="2022-07-19T22:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>acute myocardial infarction</term>
					<term>diabetes</term>
					<term>glucose</term>
					<term>HOMA</term>
					<term>insulin</term>
					<term>prognosis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>and AstraZeneca R&amp;D, Mo ¨lndal; Sweden). Prognostic role of the glucometabolic status assessed in a metabolically stable phase after a first acute myocardial infarction: the SHEEP study.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Diabetes mellitus predicts coronary heart disease (CHD) morbidity and mortality in initially healthy populations and adverse outcomes in existing CHD <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>. Diabetic patients without previous acute myocardial infarction (AMI) have as high a risk of AMI as nondiabetic patients with previous myocardial infarction <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>. It was also established that the relationship between glucose levels and cardiovascular risk in population based studies extends below the diabetic threshold <ref type="bibr" target="#b1">[2]</ref>. In AMI, increased admission glucose level or increased fasting glucose level shortly after the onset of symptoms seems to predict prognosis even in nondiabetic patients <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>. However, it is not clear whether the elevated glucose level in the early, instable phase of the myocardial infarction reflects abnormal glucose metabolism or is a marker of stress and ⁄ or severity of myocardial damage <ref type="bibr" target="#b6">[7]</ref>. Although, it has been demonstrated that oral glucose test at hospital discharge predicts the long-term glucometabolic state <ref type="bibr" target="#b14">[15]</ref>, the prognostic importance of impaired fasting glucose (IFG) evaluated at a metabolically stable phase after an AMI is not known. Detection of a possible relationship between IFG and prognosis in a stable phase would highlight the importance of even moderate disturbances in the glucose metabolism in AMI patients. On the other hand, a failure to detect such a relationship would indicate that glucose elevation below the diabetic threshold in the acute state is more related to the extent of the myocardial damage than to glucose homeostasis. Moreover, information on the possible role of insulin and insulin resistance after an AMI is sparse. In this study, we examined the role of fasting glucose, insulin levels, newly detected and known diabetes in patients surviving at least 3 months after a first AMI and follow-up for 8 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>We followed individuals enrolled as nonfatal AMI cases in the Stockholm Heart Epidemiology Program (SHEEP), a population-based case-control study of incident AMI <ref type="bibr" target="#b15">[16]</ref>. The study base comprised all Swedish citizens living in the Stockholm County, 45-70 years of age, free of previous clinically diagnosed AMI. Male cases were identified during a 2year period (1992-93) and female cases during 3 years (1992-94). Cases were identified through a special organization at the ten emergency hospitals in the region. Criteria for AMI included (i) certain symptoms according to case history information, (ii) specified changes in blood levels of the enzymes CK and LD, (iii) specified ECG-changes and (iv) autopsy findings. The diagnosis 'acute myocardial infarction' required two of the criteria (i-iii) to be met or that autopsy findings showed myocardial necrosis of an age compatible with the time of disease onset. Later comparison with a population-based incidence register indicated close to complete ascertainment of all first AMIs <ref type="bibr" target="#b16">[17]</ref>.</p><p>A questionnaire was administered in the in-hospital period. In a stable metabolic phase, 3 months after the AMI onset, a health examination measuring blood pressure, height and weight with a blood sampling was undertaken.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of the glucometabolic status</head><p>Glucose and insulin levels were determined from fasting blood samples collected at the health examination as described earlier <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18]</ref>. An estimate of insulin resistance was calculated using the homeostasis model assessment (HOMA) as follows: insulin resistance = fasting glucose*fasting insulin ⁄ 22.5 <ref type="bibr" target="#b17">[18]</ref>. Impaired fasting glucose (IFG) was defined according to the current ADA recommendation <ref type="bibr" target="#b18">[19]</ref>, i.e. fasting glucose between 5.6 and 7 mmol L )1 . Patients with fasting glucose ‡7 mmol L )1 were classified as having newly detected diabetes. Subjects were classified as having a history of diabetes if case history information from the questionnaire stated a diagnosis of diabetes with insulin or drug treatment or diet control. Patients with a fasting glucose level &lt;5.6 mmol L )1 and without a history of diabetes were classified as normoglycemic (NG). Insulin and HOMA values were categorized as quartiles in the subsequent analyses. A total of 1167 patients surviving 3 months had valid data on the glucometabolic status.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Covariates</head><p>Lipids, coagulation factors and inflammatory markers were determined from blood samples undertaken during the health examination as previously described elsewhere <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18]</ref>. Hypertension. Hypertension was defined as (i) being on antihypertensive drug therapy, for the reason of hypertension, when included in the study; (ii) a history of regular antihypertensive drug therapy during the last 5 years (or a part of that time); (iii) a systolic blood pressure ‡170 mmHg or a diastolic blood pressure ‡95 mmHg. Blood pressure values were the mean of two readings in supine position after 5 min rest. Obesity. Subjects over 30 kg m )2 were classified as being obese. Physical inactivity. Questions about physical activity included conditions at work, household and homework and leisure time activities. In the present paper, subjects who reported inactive leisure time including occasional walks, during the last 5-10 years were categorized as 'exposed' to physical inactivity. Smoking. Subjects who had never smoked regularly (i.e. for at least 1 year) were considered as never-smokers. Subjects, who smoked when included into the study, or had stopped smoking within the last 2 years, were classified as smokers. Subjects, who had stopped smoking for more than 2 years before inclusion, were classified as ex-smokers. Socio-economic position. As a measure of socio-economic position, we classified educational attainment as mandatory school only versus high school, college or university.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Follow-up</head><p>The centralized health care system in Sweden provides virtually complete follow-up information for all patients by matching their unique ten digit person identification numbers to health care registers. The average follow-up from the AMI was 8 years. Allcause and cardiac mortality was used as a primary end-point as provided by the National Cause-of-death Register. Patients were also followed for nonfatal AMI using the Swedish Myocardial Infarction Register <ref type="bibr" target="#b19">[20]</ref>. Information on hospitalization for heart failure (ICD-9 and 10 codes were 428, I50 respectively) and stroke (431, 434, I64, I63, I61) was derived from the national Swedish Hospital Discharge Register <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>. Follow-up was closed on December 1st 2001.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p>We used un-, gender ⁄ age-and multivariable-adjusted Cox proportional hazard models to examine the prognostic role of the glucometabolic status. Patients with a history of diabetes, newly detected diabetes or IFG were compared to normoglycemic patients. Insulin and HOMA were analyzed as quartiles with the lowest quartile as the reference category. Selection of covariates in the multiadjusted models was based (i) on previous knowledge about their potential relationship with the measures of glucometabolic status and outcome and (ii) on the change in the point estimate strategy <ref type="bibr" target="#b23">[24]</ref>. Proportionality of hazards was investigated visually by log-log curves and by formal tests of interaction with time. We found no evidence against the assumption that the risks associated with different levels of the glucometabolic status are stable over time. Statistical analyses were performed using sas 9 for Windows (SAS Institute Inc., Cary, NC, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Table <ref type="table" target="#tab_0">1</ref> presents the characteristics of patients with NG, IFG, newly detected diabetes and history of diabetes respectively. Patients with newly detected diabetes were the youngest and patients with history of diabetes were the oldest. Patients with NG had lower BMI and, in general, a more favourable lipid profile, lower prevalence of sedentary lifestyle and hypertension, higher education and lower levels of fibrinogen, CRP, insulin and HOMA than patients in the rest of the groups. Overall, these values were the highest amongst patients with newly detected or old diabetes and IFG was an intermediate group.</p><p>Table <ref type="table" target="#tab_1">2</ref> shows unadjusted proportions of participants who died, sustained nonfatal AMI or were hospitalized for heart failure or stroke during follow-up. All-cause and cardiac mortality gradually increased across the groups of patients with NG, IFG, newly detected and old diabetes. Nonfatal reinfarction showed a similar trend as well as hospitalization for heart failure. Figure <ref type="figure">1</ref> shows the cumulative survival according to fasting glucose values and diabetic status.</p><p>In Table <ref type="table" target="#tab_2">3</ref>, we present un-, gender ⁄ age-and multivariable-adjusted hazard ratios associated with IFG, newly detected and old diabetes with NG as the reference group. Patients with IFG showed a moderate trend towards higher total and cardiac mortality. As a secondary analyses, we divided the IFG group for those having fasting glucose between 5.6-6.1 mmol L )1 and those with 6.1-7 mmol L )1 . We found that the point estimates of risk for adverse events were not materially different between these groups. For example, hazard ratios in the multiadjusted models were 1.27 (0.79-2.05) and 1.47 (0.90-2.42) for total mortality and 1.55 (0.84-2.85) and 1.14 (0.55-2.39) for cardiac mortality in these two groups of IFG when compared with NG respectively.</p><p>Both newly detected and old diabetes was characterized with an increased risk for total and cardiac mortality, new AMI and heart failure. Associations with cardiac mortality, new AMI and hospitalization for heart failure were somewhat stronger for patients with a history of diabetes when compared to those with newly detected diabetes.</p><p>Table <ref type="table" target="#tab_3">4</ref> and 5 present the risk for adverse outcomes associated with insulin and HOMA quartiles respectively. Both insulin and HOMA were associated to adverse outcomes, especially for heart failure and cardiac mortality. However, when we repeated these analyses excluding patients with old or newly detected diabetes, we found that the effect of insulin and HOMA had substantially decreased. For example, hazard ratios for cardiac mortality for the second, third and fourth insulin quartiles when compared with the first one were 1.45 (0.67-3.16), 1.62 (0.70-3.73) and 1.35 (0.52-3.52) respectively (P for trend = 0.44). The corresponding numbers for the HOMA quartiles were 1.78 (0.83-3.83), 1.26 (0.53-2.99) and 1.43 (0.50-4.12) respectively (P for trend = 0.63). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>We found that history of diabetes and newly detected diabetes was associated with a markedly increased long-term mortality amongst survivors of a first AMI.</p><p>We also observed a trend towards increased mortality amongst IFG patients when compared to patients with normal glucose levels. Similar patterns were seen for other outcomes than death, especially for new AMI and hospitalization for heart failure.</p><p>Compelling evidence suggests that diabetes is a strong adverse prognostic factor after an AMI <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b24">25]</ref>. As overviewed by Capes et al. <ref type="bibr" target="#b6">[7]</ref> and confirmed by more recent studies <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>, elevated admission and ⁄ or fasting glucose levels measured in the early phase of AMI, i.e. within a few days after the admission, also seem to predict poor prognosis even in nondiabetic patients. However, the role of hyperglycemia in the early phase is a complex issue. Acute stress because of the MI may raise blood glucose levels but higher stress is also accompanied with higher cathecolamine levels, which could impair endothelial function, myocardial metabolism or coagulation <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b25">26]</ref>. Hyperglycemic patients during the acute phase of AMI may have higher free fatty acid concentrations, which together with hyperglycemia itself can have deleterious effects on the myocardium <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b27">28]</ref>. It is also possible that higher glucose level in the acute phase is simply a marker of the severity of myocardial damage <ref type="bibr" target="#b6">[7]</ref>. Therefore, it is not possible to generalize the results on admission glucose or fasting glucose measured a few days after the onset to a metabolically more stable phase. To the best of knowledge, the present study is the first to investigate directly the prognostic role of IFG evaluated in a stable phase, i.e. 3 months after an AMI.</p><p>The role of impaired glucose metabolism was evaluated in other stable nondiabetic CHD populations. Lenzen et al. <ref type="bibr" target="#b28">[29]</ref> could not identify impaired fasting glucose or impaired glucose tolerance without diabetes as an adverse prognostic factor in patients admit-ted to cardiology outpatient clinics with coronary artery disease. In contrast, Fisman et al. <ref type="bibr" target="#b29">[30]</ref> demonstrated that fasting glucose is a strong predictor of mortality amongst nondiabetic patients with a history of myocardial infarction or with a documented coronary heart disease. Arcavi et al. <ref type="bibr" target="#b30">[31]</ref> also concluded that IFG predicts adverse outcomes in patients with an established coronary artery disease. Similarly, Port et al. <ref type="bibr" target="#b31">[32]</ref> investigated nondiabetic participants from the Framingham Heart Study who reported CHD, stroke, congestive heart failure or intermittent claudication and found a steep increase in risk associated with glucose level through the whole range with no indication of a threshold. Moreover, IFG seems to be a predictor of outcome in CHD patients undergoing revascularization procedures <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34]</ref>.</p><p>Generally, we found a weaker adverse effect of IFG than the earlier studies. However, direct comparison of the results of the present and that of the earlier studies is difficult. We investigated uniquely a stable metabolic phase of an AMI, and we also used a lower cut off value of fasting glucose concentration to define IFG than the majority of earlier studies. In our alternative analyses, we found no indication that the level of glucose between 6.1 and 7 mmol L )1 would be a stronger predictor of adverse outcomes than that of between 5.6 and 6.1 mmol L )1 . Therefore, our findings provided some further support for the current ADA definition of using the lower threshold <ref type="bibr" target="#b18">[19]</ref>. This is in contrast to the findings of Verges et al. <ref type="bibr" target="#b10">[11]</ref> who similarly to us divided the IFG category to fasting glucose levels between 5.6-6.1 mmol L )1 and 6.1-7 mmol L )1 . The authors concluded that only the latter one was associated with increased risk for shortterm mortality after AMI.</p><p>Previous results are conflicting whether patients with newly detected or those with known diabetes are at a greater risk. According to some studies <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b11">12]</ref>, admission plasma glucose above 11 mmol L )1 is more dangerous if newly detected compared to old diabetes. On the other hand, Lenzen et al. <ref type="bibr" target="#b28">[29]</ref> found that CHD patients with newly diagnosed diabetes had lower mortality than patients with known diabetes. In the present study, history of diabetes mellitus and newly detected diabetes had a similar association to total mortality. Associations with cardiac mortality, new AMI and hospitalization for heart failure were stronger amongst patients with a history of diabetes.</p><p>We found that both fasting insulin and HOMA were associated to adverse outcomes. This was especially true for heart failure and cardiac mortality. However, when we restricted our analyses to patients without old or newly detected diabetes these associations weakened substantially. Few studies reported on the association between insulin or insulin resistance and AMI prognosis. Kragelund et al. <ref type="bibr" target="#b34">[35]</ref> concluded that fasting insulin predicts mortality in nondiabetic AMI patients. Stubbs et al. <ref type="bibr" target="#b35">[36]</ref> found that the insulin resistance is an important predictive measure of poor outcome in AMI patients without diabetes and is superior to admission glucose. It should be mentioned that these studies were performed a few days after the event and insulin levels are also known to be affected by the metabolic disturbances in the acute phase <ref type="bibr" target="#b27">[28]</ref>.</p><p>There several potential routes by which hyperglycemia, increased insulin and insulin resistance may impact upon the cardiovascular system. These include glucosylation of LDL and clotting factors <ref type="bibr" target="#b1">[2]</ref>, increased oxidative stress and mimicking the proinflammatory effects of citokines <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>, decreased fibrinolysis <ref type="bibr" target="#b39">[40]</ref> or elevation in inflammatory markers <ref type="bibr" target="#b40">[41]</ref>. It is not clear from our results whether hyperglycemia below the diabetic threshold has adverse effects itself or it is merely a predictor of future diabetes <ref type="bibr" target="#b1">[2]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p>Potential limitations of our study need to be considered. We relied on fasting glucose levels and did not perform an oral glucose tolerance test. Although this is in accordance with the current ADA recommendations <ref type="bibr" target="#b18">[19]</ref>, Bartnik et al. <ref type="bibr" target="#b8">[9]</ref> found that oral glucose tolerance test is a superior predictor of adverse events after AMI than fasting glucose.</p><p>The point estimates associated with IFG in our analyses suggest a 30-40% excess risk for both cardiac and total mortality. This would imply a biologically and clinically relevant effect. We included more patients than most previous studies, still our statistical power to detect an association between outcome and IFG was limited. This is reflected in the wide confidence intervals. Further studies are warranted to determine the prognostic importance of IFG evaluated in a stable phase after an AMI.</p><p>The low sample size for patients with newly detected diabetes is also a limitation of the present study.</p><p>Observational studies inherently limit causal inference. Although we adjusted for several potential confounders in our multivariable analyses, we were not able to assure that all potential confounding is controlled for. However, any remaining confounder potentially able to influence our results considerably would need to be strongly associated with glucometabolic status and prognosis of AMI and generally unrelated to the factors included in our models.</p><p>To document adverse outcomes during the follow up, we relied on national Swedish registries that have been validated, but are nonetheless prone to misclassification. This -supposedly random -misclassification may partly explain the weak associations with stroke. It should also be emphasized that there were only few cases of stroke amongst subjects with a history of diabetes resulting in wide confidence intervals for hazard ratios. Because of the relatively small number of cases, it was not meaningful to distinguish between ischaemic and haemorrhagic stroke.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>We confirmed that both known and newly detected diabetes are strong prognostic factors in AMI. In addition, our findings suggest that glucose levels below the diabetes cut off value might predict poor long-term prognosis when assessed in a metabolically stable phase.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Characteristics of the study participants according to their fasting glucose values and diabetic status</figDesc><table><row><cell>Glucose</cell><cell>£5.6 mmol L )1</cell><cell>5.6-7 mmol L )1</cell><cell>&gt;7 mmol L )1</cell><cell>History of diabetes</cell></row><row><cell>n</cell><cell>687</cell><cell>251</cell><cell>68</cell><cell>161</cell></row><row><cell></cell><cell>Mean (SD)</cell><cell>Mean (SD)</cell><cell>Mean (SD)</cell><cell>Mean (SD)</cell></row><row><cell>Age (years)</cell><cell>59.3 (7.3)</cell><cell>59.6 (7.1)</cell><cell>58.1 (7.6)</cell><cell>60.3 (7.0)</cell></row><row><cell>BMI (kg m )2 )</cell><cell>26.0 (3.8)</cell><cell>27.8 (4.0)</cell><cell>28.3 (4.7)</cell><cell>28.1 (4.7)</cell></row><row><cell>Peak CK (ng mL )1 )</cell><cell>28.7 (28.0)</cell><cell>28.2 (26.3)</cell><cell>27.0 (28.0)</cell><cell>23.1 (24.9)</cell></row><row><cell>Serum levels of</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total cholesterol</cell><cell>6.15 (1.11)</cell><cell>6.38 (1.18)</cell><cell>6.28 (1.52)</cell><cell>6.12 (1.29)</cell></row><row><cell>Triglycerides (mmol L )1 )</cell><cell>1.79 (1.09)</cell><cell>2.21 (1.21)</cell><cell>3.29 (3.51)</cell><cell>2.36 (1.78)</cell></row><row><cell>HDL cholesterol (mmol L )1 )</cell><cell>1.11 (0.31)</cell><cell>1.05 (0.31)</cell><cell>0.99 (0.29)</cell><cell>1.03 (0.28)</cell></row><row><cell>Lipoprotein(a) (g L )1 )</cell><cell>0.31 (0.36)</cell><cell>0.27 (0.34)</cell><cell>0.25 (0.30)</cell><cell>0.28 (0.36)</cell></row><row><cell>Apo A (g L )1 )</cell><cell>1.41 (0.26)</cell><cell>1.39 (0.25)</cell><cell>1.37 (0.30)</cell><cell>1.34 (0.21)</cell></row><row><cell>Apo B (g L )1 )</cell><cell>1.62 (0.37)</cell><cell>1.68 (0.38)</cell><cell>1.75 (0.50)</cell><cell>1.64 (0.48)</cell></row><row><cell>Fibrinogen (g L )1 )</cell><cell>3.68 (0.85)</cell><cell>3.81 (0.91)</cell><cell>3.87 (0.97)</cell><cell>3.93 (0.87)</cell></row><row><cell>hsCRP (mg L )1 )</cell><cell>3.79 (7.18)</cell><cell>4.03 (6.11)</cell><cell>5.13 (7.91)</cell><cell>4.10 (4.58)</cell></row><row><cell>Insulin (lU mL )1 )</cell><cell>9.7 (6.0)</cell><cell>14.7 (9.5)</cell><cell>23.0 (14.7)</cell><cell>23.8 (20.5)</cell></row><row><cell>HOMA</cell><cell>2.11 (1.40)</cell><cell>3.99 (2.66)</cell><cell>9.56 (8.34)</cell><cell>9.26 (8.62)</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Male gender</cell><cell>474 (69.0)</cell><cell>188 (74.9)</cell><cell>45 (66.2)</cell><cell>107 (66.5)</cell></row><row><cell>Hypertension</cell><cell>240 (36.2)</cell><cell>93 (38.6)</cell><cell>23 (41.8)</cell><cell>87 (54.4)</cell></row><row><cell>Obesity (BMI &gt; 30 kg m )2 )</cell><cell>90 (13.1)</cell><cell>62 (24.7)</cell><cell>21 (30.9)</cell><cell>51 (31.7)</cell></row><row><cell>Sedentary Lifestyle</cell><cell>274 (41.5)</cell><cell>120 (50.2)</cell><cell>32 (57.1)</cell><cell>83 (51.9)</cell></row><row><cell>Cigarette smoking</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nonsmokers</cell><cell>179 (26.8)</cell><cell>49 (20.3)</cell><cell>9 (16.1)</cell><cell>50 (31.1)</cell></row><row><cell>Previous smokers</cell><cell>170 (25.5)</cell><cell>55 (22.7)</cell><cell>10 (17.9)</cell><cell>57 (35.4)</cell></row><row><cell>Current smokers</cell><cell>319 (47.8)</cell><cell>138 (57.0)</cell><cell>37 (66.1)</cell><cell>54 (33.5)</cell></row><row><cell>High School ⁄ College or University</cell><cell>223 (33.6)</cell><cell>74 (30.6)</cell><cell>17 (30.4)</cell><cell>43 (27.2)</cell></row><row><cell>Index hospitalization</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Q wave infarction</cell><cell>368 (58.0)</cell><cell>136 (58.6)</cell><cell>39 (60.9)</cell><cell>78 (55.3)</cell></row><row><cell>Ventricular tachycardia</cell><cell>57 (8.6)</cell><cell>18 (7.3)</cell><cell>2 (3.2)</cell><cell>9 (5.8)</cell></row><row><cell>Killip classification</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>424 (72.7)</cell><cell>153 (72.2)</cell><cell>44 (72.1)</cell><cell>92 (65.3)</cell></row><row><cell>2</cell><cell>133 (22.8)</cell><cell>52 (24.5)</cell><cell>12 (19.7)</cell><cell>39 (27.7)</cell></row><row><cell>3</cell><cell>20 (3.4)</cell><cell>7 (3.3)</cell><cell>3 (4.9)</cell><cell>10 (7.1)</cell></row><row><cell>4</cell><cell>6 (1.0)</cell><cell>0 (0.0)</cell><cell>2 (3.3)</cell><cell>0 (0)</cell></row><row><cell>Regular medication use</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Beta-blockers</cell><cell>549 (79.9)</cell><cell>205 (81.7)</cell><cell>50 (73.5)</cell><cell>109 (67.7)</cell></row><row><cell>Aspirin</cell><cell>507 (73.8)</cell><cell>194 (77.3)</cell><cell>49 (72.1)</cell><cell>109 (67.7)</cell></row><row><cell>Ca antagonist</cell><cell>57 (8.3)</cell><cell>18 (7.2)</cell><cell>7 (10.3)</cell><cell>22 (13.7)</cell></row><row><cell>Diuretics</cell><cell>214 (25.7)</cell><cell>35 (33.7)</cell><cell>19 (27.9)</cell><cell>78 (28.8)</cell></row><row><cell>Digitalis</cell><cell>16 (2.3)</cell><cell>7 (2.8)</cell><cell>3 (4.4)</cell><cell>9 (5.6)</cell></row><row><cell>ACE inhibitors</cell><cell>78 (11.4)</cell><cell>18 (7.2)</cell><cell>8 (11.8)</cell><cell>22 (13.7)</cell></row></table><note>BMI, body mass index; HDL, high density lipoprotein; hsCRP, high sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor 1; tPA, tissue plasminogen activator; HOMA, homeostatis model assessment, insulin resistance ¼ fasting glucose • fasting insulin ⁄ 22.5.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>Adverse outcomes dur-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ing the follow-up amongst</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>History of</cell></row><row><cell>SHEEP patients according to</cell><cell>Glucose</cell><cell>£5.6 mmol L )1</cell><cell>5.6-7 mmol L )1</cell><cell>&gt;7 mmol L )1</cell><cell>diabetes</cell></row><row><cell>their fasting glucose values and</cell><cell>n</cell><cell>687</cell><cell>251</cell><cell>68</cell><cell>161</cell></row><row><cell>diabetic status</cell><cell>All-cause death</cell><cell>99 (14.4)</cell><cell>49 (19.5)</cell><cell>22 (32.4)</cell><cell>49 (30.4)</cell></row><row><cell></cell><cell>Cardiac death</cell><cell>52 (7.6)</cell><cell>27 (10.8)</cell><cell>10 (14.7)</cell><cell>32 (19.9)</cell></row><row><cell></cell><cell>At least one nonfatal</cell><cell>128 (18.6)</cell><cell>54 (21.5)</cell><cell>18 (26.5)</cell><cell>61 (37.9)</cell></row><row><cell></cell><cell>reinfarction</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Hospitalization for heart failure</cell><cell>159 (21.8)</cell><cell>62 (24.7)</cell><cell>25 (36.8)</cell><cell>69 (42.9)</cell></row><row><cell></cell><cell>Hospitalization for stroke</cell><cell>53 (7.7)</cell><cell>31 (12.4)</cell><cell>10 (14.7)</cell><cell>21 (13.0)</cell></row><row><cell></cell><cell>Combination of cardiovascular</cell><cell>256 (37.3)</cell><cell>114 (45.4)</cell><cell>35 (51.5)</cell><cell>99 (61.5)</cell></row><row><cell></cell><cell>events</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>Fig.1Cumulative survival according to fasting glucose values and diabetic status (P &lt; 0.001, log rank test).</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Hazard ratios for adverse outcomes with 95% confidence intervals to fasting glucose values and diabetic status</figDesc><table><row><cell></cell><cell>Unadjusted HR</cell><cell>P for</cell><cell>Age and gender</cell><cell>P for</cell><cell>Multiadjusted</cell><cell>P for</cell></row><row><cell></cell><cell>(95% CI)</cell><cell>trend</cell><cell>adjusted HR (95% CI)</cell><cell>trend</cell><cell>HR (95% CI) a</cell><cell>trend</cell></row><row><cell>Total mortality (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.34 (0.95-1.89)</cell><cell></cell><cell>1.30 (0.92-1.83)</cell><cell></cell><cell>1.36 (0.93-1.99)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>2.55 (1.61-4.05)</cell><cell></cell><cell>2.83 (1.77-4.50)</cell><cell></cell><cell>2.27 (1.26-4.09)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>2.27 (1.61-3.20)</cell><cell>&lt;0.001</cell><cell>2.20 (1.56-3.10)</cell><cell>&lt;0.001</cell><cell>2.15 (1.43-3.21)</cell><cell>&lt;0.001</cell></row><row><cell>Cardiac mortality (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.41 (0.88-2.24)</cell><cell></cell><cell>1.36 (0.85-2.16)</cell><cell></cell><cell>1.36 (0.82-2.28)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>2.19 (1.11-4.31)</cell><cell></cell><cell>2.37 (1.20-4.69)</cell><cell></cell><cell>1.77 (0.76-4.15)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>2.81 (1.81-4.37)</cell><cell>&lt;0.001</cell><cell>2.76 (1.77-4.29)</cell><cell>&lt;0.001</cell><cell>2.90 (1.76-4.78)</cell><cell>&lt;0.001</cell></row><row><cell>New AMI (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.17 (0.85-1.61)</cell><cell></cell><cell>1.14 (0.83-1.57)</cell><cell></cell><cell>1.12 (0.80-1.58)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>1.54 (0.94-2.52)</cell><cell></cell><cell>1.58 (0.96-2.60)</cell><cell></cell><cell>1.27 (0.71-2.27)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>2.27 (1.67-3.08)</cell><cell>&lt;0.001</cell><cell>2.25 (1.66-3.06)</cell><cell>&lt;0.001</cell><cell>2.01 (1.43-2.82)</cell><cell>&lt;0.001</cell></row><row><cell>Stroke (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.62 (1.04-2.53)</cell><cell></cell><cell>1.57 (1.01-2.44)</cell><cell></cell><cell>1.31 (0.79-2.16)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>2.30 (1.17-4.52)</cell><cell></cell><cell>2.64 (1.33-5.22)</cell><cell></cell><cell>1.77 (0.73-4.30)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>1.88 (1.14-3.12)</cell><cell>0.004</cell><cell>1.81 (1.09-3.01)</cell><cell>0.004</cell><cell>1.50 (0.83-2.71)</cell><cell>0.15</cell></row><row><cell>Heart failure (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.14 (0.85-1.53)</cell><cell></cell><cell>1.12 (0.83-1.51)</cell><cell></cell><cell>1.13 (0.82-1.55)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>1.99 (1.30-3.04)</cell><cell></cell><cell>2.25 (1.47-3.45)</cell><cell></cell><cell>1.59 (0.96-2.65)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>2.27 (1.71-3.02)</cell><cell>&lt;0.001</cell><cell>2.17 (1.63-2.89)</cell><cell>&lt;0.001</cell><cell>1.98 (1.43-2.74)</cell><cell>&lt;0.001</cell></row><row><cell cols="2">Combination of cardiovascular events b (mmol L )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>fasting glucose £5.6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>fasting glucose 5.6-7</cell><cell>1.25 (1.00-1.56)</cell><cell></cell><cell>1.22 (0.98-1.52)</cell><cell></cell><cell>1.11 (0.87-1.42)</cell><cell></cell></row><row><cell>fasting glucose &gt;7</cell><cell>1.65 (1.16-2.34)</cell><cell></cell><cell>1.75 (1.23-2.50)</cell><cell></cell><cell>1.30 (0.85-1.98)</cell><cell></cell></row><row><cell>History of diabetes</cell><cell>2.05 (1.62-2.58)</cell><cell>&lt;0.001</cell><cell>2.01 (1.60-2.54)</cell><cell>&lt;0.001</cell><cell>1.82 (1.40-2.36)</cell><cell>&lt;0.001</cell></row></table><note>a Multiadjustment includes age, gender, obesity, hypertension, physical activity total cholesterol, hypertension, triglycerides, apo B ⁄ apo A ratio, Q wave infarction and education. b Combination of cardiovascular events included cardiac mortality, new AMI, stroke and heart failure.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc>Hazard ratios for adverse outcomes with 95% confidence intervals across the insulin quartiles Multiadjustment includes age, gender, obesity, hypertension, physical activity total cholesterol, hypertension, triglycerides, apo B ⁄ apo A ratio, Q wave infarction and education. b Combination of events included cardiac mortality, new AMI, stroke and heart failure.</figDesc><table><row><cell></cell><cell>Unadjusted</cell><cell>P for</cell><cell>Age and gender</cell><cell>P for</cell><cell>Multiadjusted</cell><cell>P for</cell></row><row><cell>Insulin quartiles</cell><cell>HR (95% CI)</cell><cell>trend</cell><cell>adjusted HR (95% CI)</cell><cell>trend</cell><cell>HR (95% CI) a</cell><cell>trend</cell></row><row><cell>Total mortality (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>1.36 (0.85-2.17)</cell><cell></cell><cell>1.34 (0.83-2.14)</cell><cell></cell><cell>1.23 (0.74-2.05)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.50 (0.92-2.43)</cell><cell></cell><cell>1.57 (0.96-2.55)</cell><cell></cell><cell>1.39 (0.81-2.37)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>1.67 (1.06-2.63)</cell><cell>0.03</cell><cell>1.72 (1.09-2.73)</cell><cell>0.02</cell><cell>1.35 (0.76-2.37)</cell><cell>0.28</cell></row><row><cell>Cardiac mortality (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>1.68 (0.86-3.27)</cell><cell></cell><cell>1.67 (0.86-3.26)</cell><cell></cell><cell>1.55 (0.75-3.18)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.81 (0.91-3.58)</cell><cell></cell><cell>1.90 (0.95-3.77)</cell><cell></cell><cell>1.83 (0.86-3.88)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>1.99 (1.04-3.81)</cell><cell>0.05</cell><cell>2.06 (1.08-3.96)</cell><cell>0.03</cell><cell>2.03 (0.94-4.40)</cell><cell>0.07</cell></row><row><cell>New AMI (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>1.46 (0.96-2.20)</cell><cell></cell><cell>1.45 (0.96-2.19)</cell><cell></cell><cell>1.46 (0.95-2.27)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.12 (0.71-1.76)</cell><cell></cell><cell>1.13 (0.72-1.79)</cell><cell></cell><cell>0.96 (0.58-1.60)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>1.76 (1.18-2.63)</cell><cell>0.02</cell><cell>1.79 (1.20-2.67)</cell><cell>0.01</cell><cell>1.64 (1.02-2.65)</cell><cell>0.15</cell></row><row><cell>Stroke (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>0.81 (0.44-1.49)</cell><cell></cell><cell>0.79 (0.43-1.46)</cell><cell></cell><cell>0.74 (0.38-1.44)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.42 (0.80-2.51)</cell><cell></cell><cell>1.47 (0.83-2.61)</cell><cell></cell><cell>1.15 (0.59-2.22)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>1.17 (0.67-2.06)</cell><cell>0.26</cell><cell>1.23 (0.70-2.17)</cell><cell>0.18</cell><cell>1.05 (0.52-2.13)</cell><cell>0.65</cell></row><row><cell>Heart failure (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>1.47 (1.00-2.17)</cell><cell></cell><cell>1.42 (0.96-2.09)</cell><cell></cell><cell>1.48 (0.97-2.24)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.42 (0.95-2.14)</cell><cell></cell><cell>1.42 (0.94-2.14)</cell><cell></cell><cell>1.18 (0.75-1.85)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>2.12 (1.46-3.07)</cell><cell>&lt;0.001</cell><cell>2.16 (1.49-3.12)</cell><cell>&lt;0.001</cell><cell>1.77 (1.14-2.76)</cell><cell>0.04</cell></row><row><cell cols="2">Combination of all events b (lU mL )1 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile &lt;6</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile 6-10</cell><cell>1.12 (0.84-1.49)</cell><cell></cell><cell>1.09 (0.82-1.46)</cell><cell></cell><cell>1.09 (0.74-1.45)</cell><cell></cell></row><row><cell>third quartile 10-15</cell><cell>1.15 (0.85-1.55)</cell><cell></cell><cell>1.15 (0.85-1.56)</cell><cell></cell><cell>0.95 (0.68-1.32)</cell><cell></cell></row><row><cell>fourth quartile &gt;15</cell><cell>1.54 (1.17-2.03)</cell><cell>0.002</cell><cell>1.58 (1.20-2.07)</cell><cell>&lt;0.001</cell><cell>1.37 (0.98-1.91)</cell><cell>0.13</cell></row></table><note>a</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc>Hazard for adverse outcomes with 95% confidence intervals across the HOMA quartiles Multiadjustment includes age, gender, obesity, hypertension, physical activity total cholesterol, hypertension, triglycerides, apo B ⁄ apo A ratio, Q wave infarction and education. b Combination of events included cardiac mortality, new AMI, stroke and heart failure.</figDesc><table><row><cell></cell><cell>Unadjusted</cell><cell>P for</cell><cell>Age and gender</cell><cell>P for</cell><cell>Multiadjusted</cell><cell>P for</cell></row><row><cell>HOMA quartiles</cell><cell>HR (95% CI)</cell><cell>trend</cell><cell>adjusted HR (95% CI)</cell><cell>trend</cell><cell>HR (95% CI) a</cell><cell>trend</cell></row><row><cell>Total mortality</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.34 (0.81-2.22)</cell><cell></cell><cell>1.29 (0.78-2.13)</cell><cell></cell><cell>1.28 (0.74-2.21)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>1.30 (0.79-2.14)</cell><cell></cell><cell>1.25 (0.76-2.07)</cell><cell></cell><cell>1.18 (0.67-2.09)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>2.16 (1.36-3.42)</cell><cell>0.001</cell><cell>2.17 (1.37-3.45)</cell><cell>0.001</cell><cell>1.99 (1.11-3.58)</cell><cell>0.04</cell></row><row><cell>Cardiac mortality</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.68 (0.84-3.34)</cell><cell></cell><cell>1.62 (0.81-3.23)</cell><cell></cell><cell>1.73 (0.81-3.71)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>1.38 (0.67-2.80)</cell><cell></cell><cell>1.35 (0.66-2.75)</cell><cell></cell><cell>1.44 (0.64-3.24)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>2.56 (1.34-4.89)</cell><cell>0.01</cell><cell>2.59 (1.35-4.95)</cell><cell>0.01</cell><cell>3.01 (1.36-6.70)</cell><cell>0.01</cell></row><row><cell>New AMI</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.15 (0.75-1.75)</cell><cell></cell><cell>1.12 (0.73-1.70)</cell><cell></cell><cell>1.21 (0.77-1.91)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>0.79 (0.50-1.25)</cell><cell></cell><cell>0.77 (1.49-1.22)</cell><cell></cell><cell>0.73 (0.44-1.22)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>1.76 (1.19-2.60)</cell><cell>0.02</cell><cell>1.76 (1.19-2.60)</cell><cell>0.02</cell><cell>1.65 (1.02-2.67)</cell><cell>0.18</cell></row><row><cell>Stroke</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.45 (0.76-2.76)</cell><cell></cell><cell>1.40 (0.73-2.65)</cell><cell></cell><cell>1.20 (0.60-2.38)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>1.40 (0.74-2.66)</cell><cell></cell><cell>1.37 (0.72-2.60)</cell><cell></cell><cell>1.17 (0.57-2.42)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>1.75 (0.93-3.27)</cell><cell>0.11</cell><cell>1.75 (0.94-3.28)</cell><cell>0.10</cell><cell>1.29 (0.58-2.88)</cell><cell>0.56</cell></row><row><cell>Heart failure</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.34 (0.89-1.99)</cell><cell></cell><cell>1.26 (0.84-1.87)</cell><cell></cell><cell>1.31 (0.85-2.03)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>1.09 (0.72-1.65)</cell><cell></cell><cell>1.04 (0.68-1.57)</cell><cell></cell><cell>1.01 (0.63-1.61)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>2.26 (1.56-3.27)</cell><cell>&lt;0.001</cell><cell>2.25 (1.55-3.25)</cell><cell>&lt;0.001</cell><cell>1.93 (1.22-3.05)</cell><cell>0.02</cell></row><row><cell>Combination of all events b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>first quartile (&lt;1.46)</cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell><cell>1.00</cell><cell></cell></row><row><cell>second quartile (1.46-2.40)</cell><cell>1.15 (0.86-1.55)</cell><cell></cell><cell>1.09 (0.81-1.47)</cell><cell></cell><cell>1.08 (0.79-1.49)</cell><cell></cell></row><row><cell>third quartile (2.40-4.31)</cell><cell>0.93 (0.68-1.25)</cell><cell></cell><cell>0.89 (0.65-1.20)</cell><cell></cell><cell>0.82 (0.58-1.16)</cell><cell></cell></row><row><cell>fourth quartile (&gt;4.31)</cell><cell>1.77 (1.34-2.33)</cell><cell>0.001</cell><cell>1.77 (1.34-2.33)</cell><cell>0.001</cell><cell>1.56 (1.10-2.20)</cell><cell>0.07</cell></row></table><note>a</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 265; 465-475 467</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 265; 465-475 469</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 265; 465-475 471</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 265; 465-475 473</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>The SHEEP study was supported by grants from the Swedish Council for Social Research and the Swedish Council for Work Life. The county council of Stockholm also supported this study. Dr Janszky was supported by the post doc grant (2006-1146) of the Swedish Council of Working Life and Social Research, Ansgarius Foundation, King Gustaf V:s and Queen Victoria's Foundation, and the Swedish Heart and Lung Foundation. The funding organizations had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest statement</head><p>No conflict of interest was declared.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Hyperglycaemia and cardiovascular disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bartnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Norhammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">262</biblScope>
			<biblScope unit="page" from="145" to="156" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years</title>
		<author>
			<persName><forename type="first">M</forename><surname>Coutinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="233" to="240" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diabetes and mortality following acute coronary syndromes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Donahoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page" from="765" to="775" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Improved but still high short and long-term mortality after myocardial infarction in patients with diabetes mellitus A time trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission</title>
		<author>
			<persName><forename type="first">A</forename><surname>Norhammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lindback</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wallentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Stenestrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1577" to="1583" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Haffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ronnemaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pyorala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laakso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="229" to="234" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Mukamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Nesto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1422" to="1427" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Capes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="773" to="778" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Wahab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Cowden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Merry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1748" to="1754" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bartnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Norhammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tenerz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ohrvik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1990" to="1997" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ravisy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="1192" to="1198" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Impact of fasting glycemia on short-term prognosis after acute myocardial infarction</title>
		<author>
			<persName><forename type="first">B</forename><surname>Verges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dentan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="2136" to="2140" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kosiborod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Rathore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Inzucchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="3078" to="3086" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prognostic value of admission plasma glucose and HbA in acute myocardial infarction</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hadjadj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coisne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mauco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="305" to="310" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Suleiman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hammerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="754" to="760" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wallander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Norhammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tenerz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="36" to="38" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group</title>
		<author>
			<persName><forename type="first">C</forename><surname>Reuterwall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hallqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahlbom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">246</biblScope>
			<biblScope unit="page" from="161" to="174" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Recent time trends in acute myocardial infarction in</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linnersjo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gustavsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reuterwall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="17" to="21" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The risk of myocardial infarction is enhanced by a synergistic interaction between serum insulin and smoking</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Bennet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brismar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hallqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reuterwall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Faire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="641" to="647" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Follow-up report on the diagnosis of diabetes mellitus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Genuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Alberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bennett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3160" to="3167" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Identification of cases of myocardial infarction: hospital discharge data and mortality data compared to myocardial infarction community registers</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nerbrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ahlmark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="114" to="120" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">National Health Data Registers: a Nordic heritage public health</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rosen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Public Health</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="81" to="85" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schaufelberger</surname></persName>
		</author>
		<author>
			<persName><surname>Sk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Koster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosengren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="300" to="307" />
			<date type="published" when="1988">1988 to 2000. 2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The validity of a diagnosis of heart failure in a hospital discharge register</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ingelsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnlov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lind</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="787" to="791" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Modern</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><surname>Epidemiology</surname></persName>
		</author>
		<author>
			<persName><surname>Boston</surname></persName>
		</author>
		<author>
			<persName><surname>Toronto</surname></persName>
		</author>
		<title level="m">Little, Brown and Company</title>
				<imprint>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Significant predictors of poor prognosis in women aged &lt; ⁄ =65 years hospitalized for an acute coronary event</title>
		<author>
			<persName><forename type="first">F</forename><surname>Al-Khalili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Svane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Janszky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Orth-Gomer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schenck-Gustafsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">252</biblScope>
			<biblScope unit="page" from="561" to="569" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Giugliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marfella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Coppola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1783" to="1790" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Gintant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Davidoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="H2876" to="H2883" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Opie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="155" to="158" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lenzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ohrvik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2969" to="2974" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Z</forename><surname>Fisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Motro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tenenbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Boyko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mandelzweig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Behar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="485" to="490" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Arcavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Behar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caspi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Reshef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Boyko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Knobler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="239" to="245" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Port</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Goodarzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Boyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Jennrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="209" to="214" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Muhlestein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Horne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="351" to="358" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Are even impaired fasting blood glucose levels preoperatively associated with increased mortality after CABG surgery?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Klerdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ivert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hammar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Barr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Owall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1513" to="1518" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kragelund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Snorgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kober</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1891" to="1897" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Significance of an index of insulin resistance on admission in non-diabetic patients with acute coronary syndromes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Stubbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alaghband-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Laycock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Collinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Noble</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="443" to="447" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aljada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ghanim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1177" to="1185" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aljada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mohanty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ghanim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="682" to="690" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mohanty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hamouda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aljada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ghanim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dandona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="2970" to="2973" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Platelet plasminogen activator inhibitor 1 in patients with type II diabetes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Jokl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laimins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Lopes-Virella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Colwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="818" to="823" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Pradhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Manson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rifai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Buring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="327" to="334" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<idno>fax: +46 8 73 73 888</idno>
		<title level="m">Norrbacka, 6th floor, Karolinska University Hospital SE-171 76</title>
				<meeting><address><addrLine>Stockholm, Sweden</addrLine></address></meeting>
		<imprint/>
		<respStmt>
			<orgName>Correspondence: Dr Imre Janszky, Department of Public Health Sciences, Karolinska Institute</orgName>
		</respStmt>
	</monogr>
	<note>e-mail: imre.janszky@ki.se</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
